Ubiquitin–proteasome system and Parkinson's disease
Identifieur interne : 004451 ( Main/Merge ); précédent : 004450; suivant : 004452Ubiquitin–proteasome system and Parkinson's disease
Auteurs : C. Warren Olanow [États-Unis] ; Kevin St. P. Mcnaught [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
English descriptors
- KwdEn :
- Age Factors, Animals, Central Nervous System (metabolism), Humans, Models, Biological, Mutation, Parkinson Disease (genetics), Parkinson Disease (metabolism), Parkinson's disease, Proteasome Endopeptidase Complex (genetics), Proteasome Endopeptidase Complex (metabolism), Ubiquitin (genetics), Ubiquitin (metabolism), alpha‐synuclein, proteasome, protein accumulation, ubiquitin.
- MESH :
- chemical , genetics : Proteasome Endopeptidase Complex, Ubiquitin.
- genetics : Parkinson Disease.
- metabolism : Central Nervous System, Parkinson Disease, Proteasome Endopeptidase Complex, Ubiquitin.
- Age Factors, Animals, Humans, Models, Biological, Mutation.
Abstract
Increasing genetic, pathological, and experimental evidence suggest that neurodegeneration in both familial and sporadic forms of Parkinson's disease (PD) may be related to a defect in the capacity of the ubiquitin–proteasome system (UPS) to clear unwanted proteins, resulting in protein accumulation, aggregation, and cytotoxicity. This concept is supported by in vitro and in vivo laboratory experiments which show that inhibition of UPS function can cause neurodegeneration coupled with the formation of Lewy body–like inclusions. This hypothesis could account for the presence of protein aggregates and Lewy bodies in PD, the other biochemical features seen in the disorder, and the age‐related vulnerability of the substantia nigra pars compacta. It also suggests novel targets for putative neuroprotective therapies for PD. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21013
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001214
- to stream Istex, to step Curation: 001214
- to stream Istex, to step Checkpoint: 001B97
- to stream PubMed, to step Corpus: 002A98
- to stream PubMed, to step Curation: 002A98
- to stream PubMed, to step Checkpoint: 002A46
- to stream Ncbi, to step Merge: 001841
- to stream Ncbi, to step Curation: 001841
- to stream Ncbi, to step Checkpoint: 001841
Links to Exploration step
ISTEX:57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ubiquitin–proteasome system and Parkinson's disease</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
<author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21013</idno>
<idno type="url">https://api.istex.fr/document/57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001214</idno>
<idno type="wicri:Area/Istex/Curation">001214</idno>
<idno type="wicri:Area/Istex/Checkpoint">001B97</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Olanow C:ubiquitin:proteasome:system</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16972273</idno>
<idno type="wicri:Area/PubMed/Corpus">002A98</idno>
<idno type="wicri:Area/PubMed/Curation">002A98</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A46</idno>
<idno type="wicri:Area/Ncbi/Merge">001841</idno>
<idno type="wicri:Area/Ncbi/Curation">001841</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001841</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Olanow C:ubiquitin:proteasome:system</idno>
<idno type="wicri:Area/Main/Merge">004451</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ubiquitin–proteasome system and Parkinson's disease</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11">2006-11</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1806">1806</biblScope>
<biblScope unit="page" to="1823">1823</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4</idno>
<idno type="DOI">10.1002/mds.21013</idno>
<idno type="ArticleID">MDS21013</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Animals</term>
<term>Central Nervous System (metabolism)</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Mutation</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson's disease</term>
<term>Proteasome Endopeptidase Complex (genetics)</term>
<term>Proteasome Endopeptidase Complex (metabolism)</term>
<term>Ubiquitin (genetics)</term>
<term>Ubiquitin (metabolism)</term>
<term>alpha‐synuclein</term>
<term>proteasome</term>
<term>protein accumulation</term>
<term>ubiquitin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Proteasome Endopeptidase Complex</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Central Nervous System</term>
<term>Parkinson Disease</term>
<term>Proteasome Endopeptidase Complex</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Animals</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Mutation</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Increasing genetic, pathological, and experimental evidence suggest that neurodegeneration in both familial and sporadic forms of Parkinson's disease (PD) may be related to a defect in the capacity of the ubiquitin–proteasome system (UPS) to clear unwanted proteins, resulting in protein accumulation, aggregation, and cytotoxicity. This concept is supported by in vitro and in vivo laboratory experiments which show that inhibition of UPS function can cause neurodegeneration coupled with the formation of Lewy body–like inclusions. This hypothesis could account for the presence of protein aggregates and Lewy bodies in PD, the other biochemical features seen in the disorder, and the age‐related vulnerability of the substantia nigra pars compacta. It also suggests novel targets for putative neuroprotective therapies for PD. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.21013"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ubiquitin–proteasome system and Parkinson's disease</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
<author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21013</idno>
<idno type="url">https://api.istex.fr/document/57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001214</idno>
<idno type="wicri:Area/Istex/Curation">001214</idno>
<idno type="wicri:Area/Istex/Checkpoint">001B97</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Olanow C:ubiquitin:proteasome:system</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ubiquitin–proteasome system and Parkinson's disease</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11">2006-11</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1806">1806</biblScope>
<biblScope unit="page" to="1823">1823</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4</idno>
<idno type="DOI">10.1002/mds.21013</idno>
<idno type="ArticleID">MDS21013</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>alpha‐synuclein</term>
<term>proteasome</term>
<term>protein accumulation</term>
<term>ubiquitin</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Increasing genetic, pathological, and experimental evidence suggest that neurodegeneration in both familial and sporadic forms of Parkinson's disease (PD) may be related to a defect in the capacity of the ubiquitin–proteasome system (UPS) to clear unwanted proteins, resulting in protein accumulation, aggregation, and cytotoxicity. This concept is supported by in vitro and in vivo laboratory experiments which show that inhibition of UPS function can cause neurodegeneration coupled with the formation of Lewy body–like inclusions. This hypothesis could account for the presence of protein aggregates and Lewy bodies in PD, the other biochemical features seen in the disorder, and the age‐related vulnerability of the substantia nigra pars compacta. It also suggests novel targets for putative neuroprotective therapies for PD. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ubiquitin-proteasome system and Parkinson's disease.</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York10029, USA. warren.olanow@mssm.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York10029</wicri:regionArea>
<wicri:noRegion>New York10029</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St P" last="Mcnaught">Kevin St P. Mcnaught</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.21013</idno>
<idno type="RBID">pubmed:16972273</idno>
<idno type="pmid">16972273</idno>
<idno type="wicri:Area/PubMed/Corpus">002A98</idno>
<idno type="wicri:Area/PubMed/Curation">002A98</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A46</idno>
<idno type="wicri:Area/Ncbi/Merge">001841</idno>
<idno type="wicri:Area/Ncbi/Curation">001841</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001841</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Olanow C:ubiquitin:proteasome:system</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Ubiquitin-proteasome system and Parkinson's disease.</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York10029, USA. warren.olanow@mssm.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York10029</wicri:regionArea>
<wicri:noRegion>New York10029</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St P" last="Mcnaught">Kevin St P. Mcnaught</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Animals</term>
<term>Central Nervous System (metabolism)</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Mutation</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Proteasome Endopeptidase Complex (genetics)</term>
<term>Proteasome Endopeptidase Complex (metabolism)</term>
<term>Ubiquitin (genetics)</term>
<term>Ubiquitin (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Proteasome Endopeptidase Complex</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Central Nervous System</term>
<term>Parkinson Disease</term>
<term>Proteasome Endopeptidase Complex</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Animals</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Mutation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Increasing genetic, pathological, and experimental evidence suggest that neurodegeneration in both familial and sporadic forms of Parkinson's disease (PD) may be related to a defect in the capacity of the ubiquitin-proteasome system (UPS) to clear unwanted proteins, resulting in protein accumulation, aggregation, and cytotoxicity. This concept is supported by in vitro and in vivo laboratory experiments which show that inhibition of UPS function can cause neurodegeneration coupled with the formation of Lewy body-like inclusions. This hypothesis could account for the presence of protein aggregates and Lewy bodies in PD, the other biochemical features seen in the disorder, and the age-related vulnerability of the substantia nigra pars compacta. It also suggests novel targets for putative neuroprotective therapies for PD.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004451 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004451 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4 |texte= Ubiquitin–proteasome system and Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |